explore -WSS

explore

author：hotspot 2025-09-29 22:46:36 - browse：756

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

knowledge

WSS

Wegovy, Zepbound and weight loss drugs that preserve muscle

Setback for rare diseases as Taysha Gene Therapies pulls back

Nobel honors Karikó and Weissman's enduring partnership

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Congress extends some pandemic preparedness programs

Ransomware attacks on hospitals: Study outlines patient impact

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

What we owe ALS patients — and why one company fell short

The high cost of giving birth even with insurance

Ransomware attacks on hospitals: Study outlines patient impact

Bright Health sells Medicare Advantage business to Molina

NYU radiologists take on the challenge of expensive MRI machines

Novavax promises a turnaround & Lilly roils the obesity market

A daunting task: navigating dual Medicare, Medicaid eligibility

The high cost of giving birth even with insurance

CRISPR pioneers react to Casgevy, first gene

leisure time

David Sabatini, ex

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Hospitals look to new technology to keep health care workers safe

CDC picks Alphabet's Verily for wasterwater surveillance contract

Medicare innovation center doesn’t save money, experts say

U.K. considers world's first use of meningitis vaccine to address gonorrhea

knowledge

hotspot

knowledge

leisure time